An observational study in Peritoneal Carcinomatosis, sponsored by Kantonsspital Winterthur KSW. Status unknown at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-20.
Sponsored by Kantonsspital Winterthur KSW · Observational
Evaluation of clinical outcome and economical aspects in the treatment of patients with peritoneal carcinomatosis.
Peritoneal carcinomatosis is a dooming finding with no hope for cure and a steadily decrease in quality of life. Cytoreductive surgery with intraperitoneal chemotherapy (CRS HIPEC) offers a small but proven chance for cure. The implementation of a CRS HIPEC and PIPAC programme in a Swiss tertiary care hospital is evaluated.
When a patient is deemed non resectable, pressurized intraperitoneal aerosol chemotherapy (PIPAC) administered laparoscopically may confer effective palliation.
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's planned enrollment of 100 is below the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →Kantonsspital Winterthur KSW is the lead sponsor of 34 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with peritoneal carcinomatosis
Exclusion Criteria:
Patients receiving cytoreductive surgery and intraoperative chemotherapy (HIPEC/PIPAC)
Postoperative surgical complications
Reporting and grading of postoperative surgical complications (according to Dindo)
Time frame: 90 days
Rehospitalisation
Rehospitalisation: (yes/no), time frame, cause of rehospitalisation
Time frame: 90 days
Disease-free survival
Time to recurrence measured since diagnosis/Intervention (in months)
Time frame: 5 years
Overall Survival
All cause mortality since diagnosis/Intervention (in months)
Time frame: 5 years
Measurement of quality of life
Validated measurements of health-related quality of life according to the EORTC manual in terms of general quality of life: EORTC-QLQ30; disease-specific quality of life: EORTC-CR29 (colorectal cancers), and health-utility (EQ-5D).
Time frame: 5 years
Cost
At the level of individual patient Cost in terms of hospital charges and expenses in Swiss Francs
Time frame: 90 days
Revenues
At the level of individual patient Revenues in Swiss Francs as billed according to the DRG and case-mix index
Time frame: 90 days
Cost-utility analysis
Calculation and comparison of QUALY (quality-adjusted life years derived from EQ-5D) for competing treatment strategies taking advantage of published figures and own data, e.g. cost of a systemic palliative chemotherapy compared to cost of an intraperitoneal chemotherapy
Time frame: 90 days
Cost-effectiveness
Aggregation of costs, charges, and revenues for the whole series and comparison with alternative treatment option as clinically relevant, chemotherapy alone and palliative surgery alone.
Time frame: 90 days
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kantonsspital Winterthur KSW